Rc(=o)n Containing (i.e., Carboxamide) (r Is C Or H) Patents (Class 514/563)
  • Patent number: 12084399
    Abstract: The invention relates to crystalline tranilast salts. The crystalline tranilast salts, their preparation and their characterization are described and shown in the figures. The invention relates to pharmaceutical compositions containing a crystalline tranilast salt of the invention and a pharmaceutically acceptable carrier. The invention also relates to methods of treatment and the use of a therapeutically effective amount of a crystalline tranilast salt of the invention for treatment. The invention also relates to a method of preparing a liquid pharmaceutical composition comprising the step of dissolving a crystalline tranilast salt of the invention in a pharmaceutically acceptable solvent and to liquid pharmaceutical compositions prepared according to that method.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: September 10, 2024
    Assignee: NUFORMIX TECHNOLOGIES LIMITED
    Inventors: Joanne Holland, Christopher Frampton
  • Patent number: 11826471
    Abstract: Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: November 28, 2023
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Zezhi Jesse Shao, Raizza Berania Florida, Ching-Yuan Li, Lee Alani Selvey
  • Patent number: 11766421
    Abstract: Pharmaceutical compositions are described, the compositions comprising therapeutically effective quantities of compounds (such as mycophenolic acid or cyclosporine) that are capable of treating, preventing, and/or or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 26, 2023
    Assignee: SURFACE OPHTHALMICS, INC.
    Inventors: Dennis Elias Saadeh, Kamran Hosseini
  • Patent number: 11730716
    Abstract: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: August 22, 2023
    Assignee: KIORA PHARMACEUTICALS GMBH
    Inventors: Stefan Sperl, Franz Obermayr
  • Patent number: 11607397
    Abstract: Methods for the treatment of leptomeningeal disease in a pediatric patient. The leptomeningeal disease may be leptomeningeal, disseminated, and/or multicentric disease (LDM) and may be associated with one or more primary CNS tumors or one or more low-grade gliomas (LGGs). The method includes administering to a patient a plurality of extraneous antineoplastons.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 21, 2023
    Assignee: Stanislaw R. Burzynski
    Inventor: Stanislaw R. Burzynski
  • Patent number: 11583535
    Abstract: Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: February 21, 2023
    Assignee: OCCURX PTY LTD
    Inventors: Darren James Kelly, David Stapleton
  • Patent number: 11578032
    Abstract: Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: February 14, 2023
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventor: Thomas Scanlan
  • Patent number: 11571403
    Abstract: In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: February 7, 2023
    Assignee: Eiger BioPharmaceuticals, Inc.
    Inventors: Xiaofeng Xiong, David A. Cory
  • Patent number: 11478437
    Abstract: The present invention is directed to compositions and formulations for hair growth. The non-aqueous, preservative-free formulations are useful for the growth of hair, eyebrows and eyelash in a variety of setting. Also provided herein are non-aqueous, preservative-free formulations and methods for the treatment of dry-eye and related symptoms.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 25, 2022
    Assignee: JENIVISION INC.
    Inventors: Weizhen Wang, David F. Woodward
  • Patent number: 11427530
    Abstract: The invention relates to an overall enantio-specific synthesis of 4-chlorokynurenine compounds, in particular L-4-chlorokynurenine, with improved yields. Large-scale syntheses are disclosed. The invention also relates to novel intermediates in the synthesis of L-4-chlorokynurenine.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: August 30, 2022
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: Daniel Levin, Peter Leeming, Emerich Eisenreich, Xuejun Karl Liu
  • Patent number: 11426371
    Abstract: The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cell death of AML cells, and induce apoptosis in AML cells. A primary compound of the invention is SACLAC: 2-chloro-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide. The bromine analog of SACLAC (SABRAC: 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide) is also useful for treating AML. SACLAC has much better activity than other know drugs used to treat AML.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 30, 2022
    Assignees: University of Virginia Patent Foundation, Universität de Barcelona, Consejo Superior de Investigaciones Cientificas (CSIC)
    Inventors: Thomas P. Loughran, Jr., Gemma Fabrias, Jose Luis Abad, Josefina Casas, David J. Feith, Su-Fern Tan, Jennifer M. Pearson, Antonio Delgado Cirilo
  • Patent number: 11331289
    Abstract: The present invention relates to a new topical composition comprising niclosamide and/or oxyclozanide and to the use of said composition for the treatment or prevention of pyoderma or dermatitis in non-human mammals.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: May 17, 2022
    Assignees: CEVA SANTE ANIMALE, UNION THERAPEUTICS A/S
    Inventors: Jérôme Guyonnet, Claudine Zemiriline, Pascal Butty
  • Patent number: 11266645
    Abstract: Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided. The methods entail administering to the patient an effective amount of cerdulatinib.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: March 8, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Gregory Coffey, Matthew Birrell, Pamela B. Conley, John T. Curnutte, Anjali Pandey, Andrew Steele, Glenn Michelson
  • Patent number: 11077192
    Abstract: A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: August 3, 2021
    Assignee: DUSA PHARMACEUTICALS, INC.
    Inventors: Scott Lundahl, Michael Guttadauro
  • Patent number: 11007160
    Abstract: This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: May 18, 2021
    Assignee: Monash University
    Inventors: Johanna Elisabeth Fraser, David Andrew Jans, Kylie Michelle Wagstaff
  • Patent number: 11001564
    Abstract: The present invention includes novel substituted bicyclic (such as 4-substituted-chromane-8-carboxamide compounds), and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: May 11, 2021
    Assignee: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Steven Kultgen
  • Patent number: 10980735
    Abstract: The present invention relates to a skin external composition containing an extract of green tea produced by an extreme light-shielding cultivation method, which is distinguished from a conventional light-shielding cultivation method of green tea. More specifically, the present invention relates to a skin external composition, which contains an extract of green tea cultivated by extreme light-shielding, in which the amino acid content is remarkably increased by cultivating the green tea by a light-shielding cultivation under a light-shielding rate of 99% or more, thereby obtaining more excellent skin moisturizing, skin protecting, and anti-aging effects.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: April 20, 2021
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Yeong Ran Lee, Jun Seong Park, Eun Soo Lee, Nok Hyun Park
  • Patent number: 10959970
    Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: March 30, 2021
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 10905667
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: February 2, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFT
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
  • Patent number: 10881624
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: January 5, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10881657
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: January 5, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10799497
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: October 13, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10786469
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: September 29, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10780066
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: September 22, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10688042
    Abstract: A gel for topical application for alleviating food cravings is disclosed, which includes the steps of: periodically applying a gel topically to a user's skin, wherein said gel comprises: about 45.0 percent by weight of deionized water; about 10.0 percent by weight of benzyl alcohol; about 40.0 percent by weight of ethyl alcohol; about 0.2 percent by weight of tocopherol acetate; about 0.15 percent by weight of docosahexaenoic acid (DHA); about 1.15 percent by weight of resveratrol; about 1.0 percent by weight of a cross-linked polyacrylic acid copolymer; about 0.1 percent by weight of ethylenediaminetetraacetic acid (EDTA); about 200 ?L of lemon essential oil; and, from about 100 ?L to 200 ?L of triethanolamine.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: June 23, 2020
    Inventor: Antonino Cavallaro
  • Patent number: 10596167
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 24, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10555950
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 11, 2020
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • Patent number: 10548857
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: February 4, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10532073
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: January 14, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10420738
    Abstract: An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ?F508-CFTR, or another mutation of class II.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: September 24, 2019
    Assignee: INSTYTUT BIOCHEMII I BIOFIZYKI PAN
    Inventors: Norbert Odolczyk, Piotr Zielenkiewicz, Grzegorz Wieczorek, Aleksander Edelman, Danielle Tondelier, Janine Fritsch
  • Patent number: 10406086
    Abstract: Moisturizers including an acyl neutral amino acid having an acyl group with a carbon atom number of 2 to 18, and salts thereof, and cosmetics containing such a moisturizer promote the production of moisturizing-related proteins, such as filaggrin, involucrin, transglutaminase 1, keratin 10, and loricrin, and provide a moisturizing effect.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: September 10, 2019
    Assignee: Ajinomoto Co., Inc.
    Inventors: Gaku Hattori, Hiroji Ishii, Fumie Honkawa
  • Patent number: 10398667
    Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: September 3, 2019
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 10111911
    Abstract: Compositions include one or more unsaturated fatty acids and one or more nitric oxide releasing compounds. Methods for using such compositions can enhance cognitive function, reduce or prevent a decline of social interaction, reduce or prevent age-related behavioral changes, increase trainability, maintain optimal brain function, facilitate learning and memory, reduce memory loss, retard brain aging, prevent or treat strokes, and/or prevent or treat dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: October 30, 2018
    Assignee: Nestec S.A.
    Inventor: Yuanlong Pan
  • Patent number: 10098860
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: October 16, 2018
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 9968576
    Abstract: The present invention relates to a neurodegenerative disease treatment use, which is a novel use of Ramalin, and, more specifically, to a composition for preventing or treating neurodegenerative diseases, containing Ramalin, which has an inflammasome and BACE1 expression inhibitory activity. Ramalin according to the present invention has an effect of improving a cognitive ability by inhibiting the expression of an inflammatory factor, which contains an NLRP inflammasome protein, and BACE1, and is thus useful for preventing or treating memory disorder and neurodegenerative diseases.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: May 15, 2018
    Assignee: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGY
    Inventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Dong-Gyu Jo
  • Patent number: 9849144
    Abstract: Pharmaceutical compositions comprising glutamine and trehalose for treating side effects to oncology treatments are disclosed.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: December 26, 2017
    Assignee: Healios Oncology Nutrition, LLC
    Inventor: Peter Meade Anderson
  • Patent number: 9839640
    Abstract: Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: December 12, 2017
    Assignee: OccuRx Pty Ltd
    Inventors: Darren James Kelly, David Stapleton
  • Patent number: 9833426
    Abstract: An agent for enhancing NO production, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating a symptom caused by vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: December 5, 2017
    Assignee: Kyowa Hakko Bio Co., Ltd.
    Inventors: Masahiko Morita, Miho Yin Komatsu, Takahiro Hara
  • Patent number: 9526713
    Abstract: Disclosed are uses of drugs for treating thrombocytopenia, in particular the use of dencichine in preparation of drugs for treating thrombocytopenia. By adding pharmaceutically acceptable conventional adjuvant material, dencichine can be prepared into an oral preparation or an injection. A pharmacodynamic trial shows that the dencichine can effectively inhibit the thrombocytopenia caused by chemotherapy drugs, and treat thrombocytopenic purpura with obvious curative effect and low toxic side effects.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: December 27, 2016
    Assignee: KUNMING SHENGHUO PHARMACEUTICAL (GROUP) CO., LTD.
    Inventors: Guihua Lan, Feng Lan, Xiaobo Sun
  • Patent number: 9518008
    Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: December 13, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., China
    Inventors: Song Li, Wu Zhong, Zhibing Zheng, Xinbo Zhou, Junhai Xiao, Yunde Xie, Lili Wang, Xingzhou Li, Guoming Zhao, Xiaokui Wang, Hongying Liu
  • Patent number: 9447028
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor ? (RAR?) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR?, and in the treatment of diseases and conditions that are mediated by RAR?, that are ameliorated by the activation of RAR?, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: September 20, 2016
    Assignee: King's College London
    Inventors: Jonathan Patrick Thomas Corcoran, Sarkis Barret Kalindjian, Alan David Borthwick, David Reginald Adams, Jane Theresa Brown, David Michel Adrien Taddei, Jason John Shiers
  • Patent number: 9409856
    Abstract: The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBA compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including, inter alia, prevention and treatment of hormone-related diseases, cancers, inflammation, osteoporosis, peripheral vascular disease, reducing circulating lipid levels, and cardiovascular disease.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: August 9, 2016
    Assignee: Gtx, Inc.
    Inventors: James T. Dalton, Christina Herring, Duane D. Miller, Seoung-Soo Hong, Yali He, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
  • Patent number: 9402864
    Abstract: Methods of normalizing iron levels, treating iron deficiency and disorders related thereto, such as anemia, as described. Pharmaceutical compositions effective for such treatments are also described.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: August 2, 2016
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Gary M. Riley, Parshuram Rath, Michael Novinski
  • Patent number: 9381196
    Abstract: The invention encompasses a compound derived from hydroxamic acid that may be used to slow the expansion of cancer cells and thus is effective in the treatment of cancer. Generally, the disclosed compound includes a benzimidazole group coupled to a hydroxyamide of five or more unsubstituted carbon atoms and any pharmaceutically acceptable salts, solvates and chemically protected forms thereof. Also disclosed are pharmacological compositions including the compound and methods of using the compound to slow the expansion of cancer cells as well as methods of using the compound to treat cancer.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: July 5, 2016
    Assignee: The Translational Genomics Research Institute
    Inventors: Tong Wang, Stephen Gately
  • Patent number: 9375438
    Abstract: Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SURI and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: June 28, 2016
    Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Dept. of Veterans Affairs
    Inventor: J. Marc Simard
  • Patent number: 9278062
    Abstract: An eye drop composition comprising a carboxyvinyl polymer and a monoterpene, and having a viscosity from 200 to 100,000 mPa·s. The monoterpene may be at least one selected from the group consisting of menthol, camphor and borneol. The carboxyvinyl polymer content may be from 0.001 to 10 w/v % with respect to the total volume of the eye drop composition, and the monoterpene content may be from 0.0001 to 1 w/v % with respect to the total volume of the eye drop composition.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: March 8, 2016
    Assignee: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Teiko Akagi, Takayuki Miyano, Motoyoshi Inooka
  • Patent number: 9272992
    Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: March 1, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., China
    Inventors: Song Li, Wu Zhong, Zhibing Zheng, Xinbo Zhou, Junhai Xiao, Yunde Xie, Lili Wang, Xingzhou Li, Guoming Zhao, Xiaokui Wang, Hongying Liu
  • Patent number: 9254271
    Abstract: A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: February 9, 2016
    Assignee: Omeros Corporation
    Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
  • Patent number: 9248186
    Abstract: A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: February 2, 2016
    Assignee: BINYARCO, LLC
    Inventor: Jeffrey E. Binder
  • Patent number: 9233089
    Abstract: Pulmonary arterial hypertension (PAH) can be prevented in persons susceptible to the diseases and PAH patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene A4 hydrolase (LTA4H) inhibitors, leukotriene B4 receptor (BLT1/BLT2) antagonists, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxygenase activating protein (FLAP) inhibitors.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 12, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark R. Nicolls, Wen Tian, Jayakumar Rajadas